Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 89.00 88.00 90.00 91.00 88.50 91.00 1,792,018 16:23:47
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 9.8 1.2 0.8 111.3 160

Omega Diagnostics Share Discussion Threads

Showing 16001 to 16024 of 22375 messages
Chat Pages: Latest  643  642  641  640  639  638  637  636  635  634  633  632  Older
DateSubjectAuthorDiscuss
28/10/2020
07:37
Where's the jam? Best of british to all on the softie thread :-)
gwr7
28/10/2020
07:34
Just one extract: "the Company remains on track to increase capacity to produce up to 200,000 AbC-19(TM) Rapid tests per week by the end of November, with the capacity contributing to the overall target of 300,000 lateral flow tests per week mentioned above" The historic numbers are pretty irrelevant in the scheme of things - though the core Food Intolerance business is recovering well anyway in H2. Interestingly, ODX state there are "significant near-term opportunities for this business unit in China". News flow is imminent here perhaps. The ELISA test update is slightly disappointing, but ODX are "optimistic that it will see further orders materialise from DHSC and other sources, both domestic and overseas" as regards Abingdon. Re the Mologic lateral flow antibody test, "we are seeing early sales traction with this product that provides confidence for performance in the second half of the financial year." Finally, the antigen test is looking good : "by the end of November, Omega would look to commence technical transfer of the test prior to commencing manufacturing". The m/cap here is still small imo if prospects start to become tangible as hoped.
rivaldo
28/10/2020
07:30
SIGNIFICANTLY increase in revenue is the word to look at. Forward not backwards.... Would make a nice bolt on for another bigger company to buy..
onehanded
28/10/2020
07:29
RNS as expected, still lots of cash and ramping up LFT's as expected. ELISA testing sales disappointing....CD4-200 progressing and Food Intolerance heading in the right direction....
barrywhit
28/10/2020
07:28
COVID will never go !!This is the new world .. I'm afraid.
amaretto1
28/10/2020
07:28
thejaba you make a false statement ."Revenue is £3m" . Think about it that makes £6m in a year as these results are for 6 months
9degrees
28/10/2020
07:27
Great RNS imho.
hodhasharon
28/10/2020
07:16
no matter how you dress this up the facts are MC 120m, revenue 3m. Covid has brought a huge disconnect for some companies, once Covid goes its back down to earth for a lot.
thejaba
28/10/2020
07:12
The future is significant revenues !!
amaretto1
27/10/2020
14:48
is now a takeover target, would fit a larger pharmaceutical company or add to a antigen company profile. I saw a few rumours circulating, but would need to see large buys if true.
onehanded
27/10/2020
14:45
Value Target (ODX): 166-177p
valuetracker
27/10/2020
13:38
Tomorrow is a trading update, not the results - it's all about the outlook, progress re COVID tests, progress re CD4, progress in China for Food Intolerance etc. The historic numbers are almost irrelevant.
rivaldo
27/10/2020
12:30
Maybe its better that we are drifting today.The results may surprise us. Hopefully in a good way
upomega
27/10/2020
12:15
Struggling again when others up, hope this isn't a harbinger of tomorrow's presentation (or the much speculated placing).....
control1
27/10/2020
09:46
Barrywhit Dont forget they will also need a cd4200 advanced test together with a test for food allergens.
upomega
27/10/2020
08:49
If the article is correct then it looks like people will need an Antibody test every 4 to 6 months.....not great for the population but good news for Omega and other diagnostic companies...
barrywhit
27/10/2020
08:39
ok so I am thinking more tests required, which is good for odx.
thehitman1
27/10/2020
08:29
https://www.sciencemediacentre.org/expert-reaction-to-a-preprint-from-the-react-2-study-looking-at-prevalence-of-antibody-positivity-to-sars-cov-2/
dmdmdmdm1
27/10/2020
08:28
https://www.google.co.uk/amp/s/www.bbc.co.uk/news/amp/health-54696873Antibodies fall rapidly.any views on above?.
thehitman1
27/10/2020
08:21
I reckon 80p due but then the multibagger follows
ivan danko
27/10/2020
08:16
The times article is good inmo. People have got carried away inmo. Next year us the year. Not now.
upomega
27/10/2020
08:07
The Times article: There are always winners to be found in an economic crisis (Greig Cameron writes). Omega Diagnostics is one. The small Scottish life sciences group dates back to 1987 and was floated on Aim in 2006. Its interests have included kits for testing food allergies and tropical diseases. Until Covid-19, much of the hope around its prospects was in a diagnostic test for HIV indicating when drug treatment is needed. The product, which gives results without the need to use a laboratory, is becoming popular in some African countries, as well as among large non-governmental organisations. Omega’s shares sank to less than 7p in March this year as markets retreated during the initial days of the pandemic, but since then its manufacturing capacity has placed it in a strong position to help in efforts to monitor the spread of the coronavirus. It is part of the UK Rapid Test Consortium and is producing antibody tests for domestic efforts, as well as looking to export to places such as India. At the start of this month Omega said that the consortium had received its first order for a million antibody tests that can show results within 20 minutes using a small drop of blood. It expects to manufacture 175,000 for that first order and to make about 25 per cent of the orders that the consortium receives over the longer term. It says that it will have the capacity to produce 200,000 tests a week by the end of November. Finncap, the house broker, estimates that Omega will receive about £1.50 for every device, with gross margins of 50 per cent. That would mean peak weekly revenue of up to £300,000, with the broker pencilling in £5.7 million of revenue from Covid-19 test production in the year to March 2021. Omega had £9.8 million of revenue in the 12 months to the end of March this year when it made an underlying pre-tax loss of about £400,000. There are other potential growth drivers, too. Its HIV product has passed a procurement milestone for the World Health Organisation and its food allergy kits have been approved by Chinese regulators for laboratory tests. Omega shares hit 107p this month, but were down 3p, or 3 per cent, at 95p today. ADVICE Hold WHY Demand for Covid-19 testing unlikely to tail off soon
jurgenklopp
27/10/2020
07:35
Haggis is awesome. Expansion going very well. What news of who ?
oapknob1
27/10/2020
07:34
upomega, We will find out tomorrow, hopefully they won’t be too bad as it’s all about sales going forward. Fingers crossed..
barrywhit
Chat Pages: Latest  643  642  641  640  639  638  637  636  635  634  633  632  Older
ADVFN Advertorial
Your Recent History
LSE
ODX
Omega Diag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210307 21:11:04